What is ixLayer?
ixLayer offers a comprehensive direct-to-patient platform engineered to elevate the patient experience for biopharma companies. Its suite of services encompasses virtual patient engagement, telehealth capabilities, streamlined lab testing, prescription fulfillment, and benefits verification. By simplifying and accelerating the pathway to care, ixLayer aims to boost patient activation and improve compliance with diagnostic testing protocols. The platform is designed to enhance operational efficiency for its biopharma clientele, ultimately contributing to better patient outcomes and a more integrated healthcare journey.
How much funding has ixLayer raised?
ixLayer has raised a total of $75M across 1 funding round:
Series A
$75M
Series A (2021): $75M with participation from Hamid Moghadam, Zeshan Muhammedi, PearVC, Bobby Yazdani, General Catalyst, Dara Khosrowshahi, and Anne Wojcicki
Key Investors in ixLayer
General Catalyst
General Catalyst is a prominent venture capital firm known for its strategic investments in transformative companies across various sectors. They focus on backing ambitious entrepreneurs and management teams, providing not only capital but also operational expertise to foster significant growth and market impact.
PearVC
PearVC is an investment firm that likely focuses on early-stage technology companies, providing crucial seed and early-stage capital to help innovative startups develop and scale their operations.
Undisclosed investor
An undisclosed investor participated in this funding round, indicating strategic alignment or a desire for privacy in their investment activities.
What's next for ixLayer?
With the recent infusion of $75M in major strategic investment, ixLayer is poised for accelerated growth and further platform development. This enterprise-level backing, bringing the total funding to $75M, suggests a strategic focus on scaling operations, expanding market reach, and potentially enhancing its technological infrastructure. The company's trajectory indicates a move towards solidifying its position as a leader in direct-to-patient healthcare solutions, likely involving deeper integration with biopharma partners and a continued emphasis on improving patient access to diagnostics and care.
See full ixLayer company page
